NDV-ADC01-exatecan
/ NDV Therapeutics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
March 18, 2026
Targeting intracellular KRASG12D/HLA-A11 pMHC with a novel TCR-mimic antibody-drug conjugate (TCRm-ADC) demonstrates potent antitumor activity in preclinical models
(AACR 2026)
- "Additionally, NDV-ADC01-exatecan significantly elicited antitumor immunity and reshaped the tumor microenvironment when combined with low-dose radiotherapy in a humanized HLA-A*11/hB2M transgenic model. Together, these screening and engineering processes provide a novel therapeutic strategy to target undruggable KRASG12D-mutated cancers."
ADC • IO biomarker • Preclinical • Colorectal Cancer • Oncology • Solid Tumor • KRAS
1 to 1
Of
1
Go to page
1